Some novel agents for wound healing modulation in glaucoma surgery are being investigated nowadays, among which are immunosuppressants with selective mechanism of action–calcineurin inhibitor cyclosporine A (CsA) and inhibitor of mechanistic target of rapamycin (mTOR) everolimus [17,18,19,20]. This evidence concerns the gene MTOR and glaucoma.